Treatment of Candida nail infection with terbinafine

Rina Segal*, Aharon Kritzman, Lia Cividalli, Zmira Samra, Michael David

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

Background: Terbinafine is a highly potent drug against dermatophytes. Data regarding its effectiveness against Candida species are few and variable. Objective: Our purpose was to evaluate the efficacy and safety of oral terbinafine in patients with Candida nail infection. Methods: In an open-label uncontrolled study, 20 patients completed 16 weeks of treatment with terbinafine, 250 mg/day, and an additional 8 weeks with placebo. Efficacy was assessed clinically and mycologically at weeks 0 (baseline), 4, 8, 16, 24, 36, and 48. Routine laboratory studies were performed at baseline and weeks 4, 8, and 16. Results: At the end of the trial 60% of target nails were cured clinically and mycologically; in 10% there was mycologic cure with residual clinical signs, in 25% a moderate improvement (>50%), and failure in only 5% (one patient). Most nails were infected by Candida parapsilosis. Two of 28 patients showed mild reversible elevation of liver enzymes 1 month after initiation of terbinafine treatment. Conclusion: The administration of terbinafine lot 16 weeks is effective in the treatment of Candida nail infection. Liver enzyme values should be determined during the first month of treatment.

Original languageEnglish
Pages (from-to)958-961
Number of pages4
JournalJournal of the American Academy of Dermatology
Volume35
Issue number6
DOIs
StatePublished - Dec 1996

Funding

FundersFunder number
Sandoz Pharma Ltd

    Fingerprint

    Dive into the research topics of 'Treatment of Candida nail infection with terbinafine'. Together they form a unique fingerprint.

    Cite this